Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + Pembrolizumab in r/r DLBCL
NCT03340766Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2018
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL) (4 cohorts), sponsored by Amgen. Primary endpoint: Number of Participants With Dose Limiting Toxicities at 42 days. Started Mar 2018; status: completed.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03340766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340766.